Carbapenem-resistant Organisms (CRO) Screening From Rectal Swabs in Patients With Hematological Diseases in China
Launched by SIR RUN RUN SHAW HOSPITAL · Aug 4, 2021
Trial Information
Current as of June 08, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • On a certain day in each chosed hospital, all the inpatients diagnosed with hematological malignancies diseases will be enrolled
- Exclusion Criteria:
- • Patients or their legal representatives refused to enter the study
- • Patients died because of hematological malignancies diseases.
About Sir Run Run Shaw Hospital
Sir Run Run Shaw Hospital is a distinguished medical institution dedicated to advancing healthcare through innovative clinical research and high-quality patient care. As a leading sponsor of clinical trials, the hospital integrates state-of-the-art medical technology with a commitment to ethical standards and patient safety. With a multidisciplinary team of experienced healthcare professionals, Sir Run Run Shaw Hospital focuses on a wide range of therapeutic areas, aiming to contribute to medical knowledge and improve treatment outcomes. The institution fosters collaboration with academic and industry partners to drive scientific discovery and enhance the quality of life for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hangzhou, Zhejiang, China
Patients applied
Trial Officials
Yunsong YU, MD
Principal Investigator
Zhejiang University school of medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials